Our Key Panelists
John Osborne, MD, PhD, FACC, FNLA
Founder and Director of State of the Heart Cardiology, CEO of Metroplex Cardiology
Dr. Osborne is a Harvard-trained MD-PhD Cardiologist-Lipidologist with two decades of experience in clinical trials. His clinical interests include preventive cardiology, metabolic syndrome and diabetes, hypertension, congestive heart failure, cholesterol disorders, coagulation disorders, and cardiovascular genetics. He has been recognized as a Fellow of the American College of Cardiology and a Fellow of the National Lipid Association. Dr. Osborne is the founder and director of State of the Heart Cardiology in Dallas, Texas, and is currently the CEO of Metroplex Cardiology.
James K. Min, MD
Founder and Chief Executive Officer, Cleerly Inc.
Dr. Min is a globally recognized authority on cardiovascular imaging and a physician-scientist who understands the inter-relationships between non-invasive imaging, coronary angiography, and revascularization.
James P. Earls, MD
Chief Medical Officer, Cleerly Inc.
Dr. Earls is a Professor of Radiology at George Washington University Hospital and a leader within the field of Radiology in applications of advanced imaging technologies in cardiovascular care.
Plaque Phenotyping
Learn how subtypes of plaque, including calcified and noncalcified, influence cardiac event risk and disease progression.
Measuring Residual Risk
See beyond traditional measures of disease to identify those who have disease progression even with medical intervention.
The Power of Coronary CTA
Examine the benefits of noninvasive coronary CTA for aiding the diagnosis and treatment of CAD.
AI’s Role in Plaque Quantification
See how AI-enabled advanced plaque analysis can aid physicians in analyzing atherosclerosis.
Cleerly's Transforming Cardiac Care webinar series is open to any cardiologist, radiologist, or other healthcare professional with an interest in breakthrough medtech for heart disease and prevention.
Patents
Cleerly continues to revolutionize heart attack and cardiovascular disease prevention and treatment everyday by inventing world-class technology. Cleerly invests significant time and resources in research and development towards this goal. To protect Cleerly’s research and development efforts, Cleerly has vigorously developed a robust intellectual property portfolio – all part of a strategy for protecting the innovations that make Cleerly an industry leader in cardiovascular disease prevention and treatment.
Cleerly’s products and services may be covered by or for use under one or more of U.S. Patent Nos. 11,922,627, 11,948,301, 12,023,190, 11,861,833, 11,967,078, 11,832,982, 11,690,586, 11,779,292, 11,730,437, 11,672,497, 11,737,718, 11,751,826, 11,660,058, 11,896,415, 11,751,830, 11,751,829, 11,302,001, 11,308,617, 11,238,587, 11,302,002, 11,321,840, 11,341,644, 11,244,451, 11,288,799, 11,276,170, 11,210,786, 11,232,564, 11,367,190, 11,315,247, 11,969,280, 11,094,060, 11,120,550, 11,120,549, 11,132,796, 11,094,061, 11,113,811, 11,501,436, 11,751,831, 11,642,092, 11,759,161, 11,317,883, 11,350,899, 11,766,230, 11,766,229, and 10,813,612, as well as other patents that are pending.
For additional information, please contact legal@cleerlyhealth.com.
Solutions
About
© 2024 Cleerly, Inc.